Investor SentimentInvestor sentiment on GOSS has greatly contracted following Phase 2 TORREY data, making some wonder if the company can pull off a win.
Previous Study ResultsThe topline Ph.2 TORREY study data disappointed, although there were encouraging signals in severe patients.
Timeline DelaysTopline data for the PROSERA study is now expected in February 2026, causing a delay that may disappoint investors.